ASK REDCHAT ANYTHING ABOUT CELLDEX THERAPEUTICS, INC
Celldex Therapeutics, Inc (NASDAQ: CLDX)
Listen to this Section
$39.10
-0.0100
(
-0.03% )
0.0K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Barzolvolimab (CDX-0159) (KIT receptor)DetailsKIT/Mast cell diseases, Chronic spontaneous urticaria, Chronic urticaria |
Phase 3 |
| Barzolvolimab (CDX-0159)DetailsChronic inducible urticaria |
Phase 3 |
| Barzolvolimab (CDX-0159) (KIT receptor)DetailsPrurigo nodularis, Skin disease/disorder |
Phase 2 |
| Barzolvolimab (CDX-0159)DetailsEosinophilic Gastritis, Eosinophilic Esophagitis |
Phase 2 |
| Barzolvolimab (CDX-0159) (KIT receptor)DetailsSkin disease/disorder, Atopic dermatitis |
Phase 2 |
| CDX-585DetailsSolid tumor/s, Cancer |
Phase 1 |
| CDX-622DetailsInflammatory disease |
Phase 1 |
| CDX-527 (and PD-L1 / CD27)DetailsSolid tumor/s, Cancer |
Failed |
| CDX-1140 (CD40 agonist)DetailsSolid tumor/s, Cancer, Diffuse large B cell lymphoma |
Failed |
Market Data
|
| Open |
$39.10 |
| Previous Close |
$39.11 |
| Volume |
0.0K |
| Market Cap |
$3.07B |
| Day Range |
$39.12 - $39.21 |
| 52 Week Range |
$19.72 - $40.30 |
| Shares Outstanding |
78.49M |
| Change % |
-0.03% |
| Net Change |
▼ -0.0100 |
| Insider Ownership |
0.00% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| IPO Year | 1986 |
| Country | United States |
Insider Ownership Transactions
Total Amount Purchased:
11,500.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-11-12 |
Buy |
11500.00 |
Marucci Anthony S |